Former President and Chief Executive Officer (6) · Spero Therapeutics, Inc. (SPRO)

Ankit Mahadevia

A named executive officer of Spero Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,385,905

Salary $379,220Stock awards $999,998Bonus $508,000

FY2022: $4,239,705

1st of 4 named executive officers at Spero Therapeutics by FY2023 total.

4 named officers on file for Spero Therapeutics, FY2023

Ankit Mahadevia’s pay file — $29

  • 7 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spero Therapeutics’s whole pay program stands against its peers

  • Spero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Ankit Mahadevia’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ankit Mahadevia compensation by year

Spero Therapeutics Summary Compensation Table · all 7 fiscal years held
In US dollars, as Spero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$389,574$465,000$497,083$536,667$590,417$633,750$379,220
Bonus$0$0$0$0$0$254,000$508,000
Stock awards$0$0$285,023$0$1,300,000$1,499,998$999,998
Option awards$2,679,616$0$752,778$1,153,962$2,650,765$1,499,324$0
Non-equity incentive$114,000$255,750$250,000$424,049$327,618$342,900$0
Pension and deferred compensation$0$0$0$0$0$0$0
All other$1,087$574$792$6,110$6,245$9,733$498,687
Total$3,184,277$721,324$1,785,676$2,120,788$4,875,045$4,239,705$2,385,905

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed April 16, 2024, accession 0001193125-24-097749, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-24-097749. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2024.

$3.2M
$721K
$1.8M
$2.1M
$4.9M
$4.2M
$2.4M
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU531,914$781,914—
RSU100,626$147,920—
RSU39,109$57,490—
Option52,302—$19.18
Option101,687—$11.18
Option7,500—$9.34

Per the Outstanding Equity Awards at Fiscal Year-End table in Spero Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2023 proxy (filed April 16, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-08-28Sale—6,572$1.97703,294
2025-06-12Grant or award—20,000$0.00709,866
2025-02-05Sale—13,959$0.78745,126
2025-02-05Sale—55,260$0.78689,866
2024-08-27Sale—5,912$1.35759,085
2024-05-29Grant or award—20,000$0.00764,997

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Spero Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Ankit Mahadevia · this pageFormer President and Chief Executive Officer (6)$2,385,905
Satyavrat ShuklaPresident and Chief Executive Officer$2,024,647
Tamara JosephFormer Chief Legal Officer (7)$1,455,126
Timothy KeutzerChief Operating Officer$1,438,569

Board service

Spero Therapeutics board · FY2023–FY2025
Director compensation in US dollars, as Spero Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$45,000$57,800—$0$102,800
FY2024$75,000$28,400—$101,110$204,510
FY2023$0$0$0——

Each year as the company reported it in Spero Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Spero Therapeutics pays directors a $40,000 cash retainer and $20,000 in RSUs. As stated in Spero Therapeutics's FY2025 proxy.

Committees

Development

The full Spero Therapeutics compensation record

free company brief

This page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ankit Mahadevia's compensation dossier · One-time report. No refunds.